Roche expands COVID testing portfolio with $1.8bn GenMark dealRoche has said it will pay $1.8 billion for molecular testing company GenMark, boosting the Swiss company’s diagnostic Share XRoche expands COVID testing portfolio with $1.8bn GenMark dealhttps://pharmaphorum.com/news/roche-expands-covid-testing-portfolio-with-1-8bn-genmark-deal/
